Spots Global Cancer Trial Database for relapsing chronic myelogenous leukemia
Every month we try and update this database with for relapsing chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | NCT00004905 | Leukemia | filgrastim recombinant int... cyclophosphamid... cytarabine etoposide idarubicin peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| STI571 in Treating Patients With Recurrent Leukemia | NCT00004932 | Leukemia | imatinib mesyla... | - 21 Years | Children's Oncology Group | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00101231 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Recurrent Adult... Relapsing Chron... | alvocidib | 1 Year - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia | NCT00002588 | Leukemia | etoposide topotecan hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia | NCT00004052 | Leukemia | QS21 bcr-abl peptide... | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002761 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cyclosporine cytarabine idarubicin peripheral bloo... | 18 Years - 60 Years | Columbia University | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00049192 | Chronic Myeloge... Chronic Phase C... Relapsing Chron... | oblimersen sodi... imatinib mesyla... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | NCT00100997 | Leukemia | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Patients Who Have Hematologic Cancer | NCT00004047 | Leukemia Myelodysplastic... | exatecan mesyla... | - | Daiichi Sankyo | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | NCT00278330 | Blastic Phase C... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Untreated Adult... Untreated Adult... | alvocidib vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia | NCT00002693 | Leukemia Neutropenia | filgrastim carboplatin topotecan hydro... | 18 Years - | Mayo Clinic | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | NCT01426334 | Accelerated Pha... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | dasatinib diagnostic labo... pharmacological... cyclosporine | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | NCT00015847 | Leukemia | recombinant int... imatinib mesyla... | 18 Years - | OHSU Knight Cancer Institute | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | NCT00006053 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia | NCT00618696 | Leukemia Myelodysplastic... | anti-CD45 monoc... yttrium Y 90 an... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | NCT00112775 | Leukemia | dasatinib imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia | NCT00119340 | Leukemia | cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002761 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cyclosporine cytarabine idarubicin peripheral bloo... | 18 Years - 60 Years | Columbia University | |
| Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00054431 | Accelerated Pha... Blastic Phase C... Childhood Chron... Chronic Myeloge... Relapsing Chron... | imatinib mesyla... decitabine laboratory biom... | - | National Cancer Institute (NCI) | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00101088 | Accelerated Pha... Blastic Phase C... Chronic Myeloge... Chronic Phase C... Relapsing Chron... | imatinib mesyla... temsirolimus laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | NCT00006220 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | arsenic trioxid... tretinoin | 15 Years - | Washington University School of Medicine | |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | NCT00098436 | Leukemia | laromustine temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | NCT00295880 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | umbilical cord ... | 12 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | NCT00002598 | Leukemia | recombinant int... sargramostim cyclophosphamid... cytarabine etoposide methotrexate mitoxantrone hy... bone marrow abl... radiation thera... | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Topotecan in Treating Children With Refractory Leukemia | NCT00002705 | Leukemia | topotecan hydro... | - 20 Years | National Cancer Institute (NCI) | |
| Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation | NCT00002456 | Graft Versus Ho... Leukemia Lymphoma | cyclosporine methotrexate allogeneic bone... | - | Fred Hutchinson Cancer Center | |
| Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML | NCT00416884 | Leukemia | Campath Fludarabine Total Body Irra... T-Cell Deplete | 4 Years - 75 Years | OHSU Knight Cancer Institute | |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | NCT00006053 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | NCT00052598 | Accelerated Pha... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Childhood Chron... Childhood Myelo... Recurrent Adult... Recurrent Child... Relapsing Chron... Secondary Acute... | therapeutic all... aldesleukin laboratory biom... flow cytometry | - | Fred Hutchinson Cancer Center | |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | NCT00098436 | Leukemia | laromustine temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | NCT00066326 | Leukemia | imatinib mesyla... tanespimycin | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer | NCT00012376 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Paroxysmal Noct... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Thrombocytopeni... Untreated Adult... | bryostatin 1 sargramostim laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Tipifarnib in Treating Young Patients With Refractory Leukemia | NCT00022451 | Leukemia | tipifarnib | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00015834 | Blastic Phase C... Chronic Myeloge... Relapsing Chron... | imatinib mesyla... cytarabine | 18 Years - | National Cancer Institute (NCI) | |
| Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant | NCT00526292 | Leukemia Myelodysplastic... | natural killer ... cyclophosphamid... fludarabine | - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00053144 | Leukemia | cytarabine irinotecan hydr... | 15 Years - | Roswell Park Cancer Institute | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | NCT00064285 | Leukemia | alvocidib imatinib mesyla... | 18 Years - | Virginia Commonwealth University | |
| Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | NCT00345826 | Leukemia | dasatinib | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia | NCT00119340 | Leukemia | cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | NCT00098826 | Acute Undiffere... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... Untreated Adult... | ispinesib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | NCT00060372 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Atypical Chroni... Childhood Myelo... Chronic Myeloge... Disseminated Ne... Malignant Neopl... Ovarian Chorioc... Ovarian Embryon... Ovarian Immatur... Ovarian Mature ... Ovarian Mixed G... Ovarian Monoder... Ovarian Polyemb... Ovarian Yolk Sa... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Malig... Recurrent Mantl... Recurrent Neuro... Recurrent Ovari... Recurrent Ovari... Refractory Chro... Refractory Mult... Relapsing Chron... Stage I Multipl... Stage II Multip... Stage II Ovaria... Stage III Malig... Stage III Multi... Stage III Ovari... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Ovaria... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Tera... Testicular Yolk... Testicular Yolk... Testicular Yolk... | ipilimumab therapeutic all... | 18 Years - | National Cancer Institute (NCI) | |
| BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | NCT00112775 | Leukemia | dasatinib imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | NCT00816283 | Leukemia | dasatinib vorinostat cytogenetic ana... gene expression... mutation analys... reverse transcr... flow cytometry laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00012259 | Leukemia | troxacitabine | 16 Years - 120 Years | Takeda | |
| High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies | NCT00002818 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... | cytarabine deoxycytidine | 18 Years - 120 Years | Virginia Commonwealth University | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis | NCT00006475 | Leukemia | imatinib mesyla... | 18 Years - | Novartis | |
| Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | NCT00004065 | Bladder Cancer Breast Cancer Colorectal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Lung Cancer Melanoma (Skin) Ovarian Cancer Prostate Cancer Unspecified Adu... | tanespimycin | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
